肺癌患者肿瘤M2型丙酮酸激酶和乳酸脱氢酶及其同工酶的变化及其临床意义

The analysis of M2-Pyruvate kinase,lactate dehydrogenase and its isoenzymes in lung cancer

目的联合检测肺癌患者血浆中肿瘤M2型丙酮酸激酶（M2-PK）和血清中乳酸脱氢酶（LDH）及其同工酶，以评价肺癌患者糖酵解的水平。方法用夹心ELISA法检测48例肺癌患者及30例对照组血浆中M2-PK值，并用全自动生化分析仪检测LDH及其同工酶谱的变化。结果肺癌患者M2-PK水平和LDH总活性均明显高于对照组，且与临床分期相关。但二者均与肺癌的病理类型无关。Ⅲ、Ⅳ期肺癌患者血浆中M2-PK水平和LDH水平均显着高于Ⅰ、Ⅱ期。肺癌患者血清LDH同工酶谱出现H型向M型转化。结论肺癌患者糖酵解酶M2-PK、LDH及其同工酶谱检测均提示其糖酵解明显增强，其糖酵解途径的关键酶可能成为肺癌诊断及治疗的靶点。

Objective To test the plasma levelof tumor M2-Pyruvate Kinase （ Tu M2-PK ） ,serum level of Lactate Dehydronase（LDH） and its isoenzymes in lung cancer patients, in order to evaluate the glycolysis in lung cancer. Methods Forty-eight patients with lung cancer were selected for this study, thirty-one patients with benign lung disease and thirty healthy people as controls. Plasma level of Tu M2- PK（with Sandwich ELISA） and serum levels of LDHand its isoenzymes （with Sebia hydrasys autoanalysis） were determined in patients and controls. Results The plasma level of Tu M2-PK and serum LDH in patients with lung cancer were significantly higher than that in controls. And the concentrations of M2-PK and LDH were independent of the histological tumor type of lung cancer but correlated strongly with the tumor stage. Conclusion The expression of M2-PK, LDH and LDH isoenzyme is obviously higher in lung cancer patients shown that the Glycolytic process was enhanced in lung cancer. The inhibition of the glycolyric enzymes could be a potential target for early diagnosis and therapy of lung cancer.